false
2025
Q2
--12-31
0001065078
0001065078
2025-01-01
2025-06-30
0001065078
2025-08-04
0001065078
2025-06-30
0001065078
2024-12-31
0001065078
2025-04-01
2025-06-30
0001065078
2024-04-01
2024-06-30
0001065078
2024-01-01
2024-06-30
0001065078
us-gaap:CommonStockMember
2024-12-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001065078
us-gaap:RetainedEarningsMember
2024-12-31
0001065078
us-gaap:CommonStockMember
2025-03-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2025-03-31
0001065078
us-gaap:RetainedEarningsMember
2025-03-31
0001065078
2025-03-31
0001065078
us-gaap:CommonStockMember
2023-12-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001065078
us-gaap:RetainedEarningsMember
2023-12-31
0001065078
2023-12-31
0001065078
us-gaap:CommonStockMember
2024-03-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001065078
us-gaap:RetainedEarningsMember
2024-03-31
0001065078
2024-03-31
0001065078
us-gaap:CommonStockMember
2025-01-01
2025-03-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-03-31
0001065078
us-gaap:RetainedEarningsMember
2025-01-01
2025-03-31
0001065078
2025-01-01
2025-03-31
0001065078
us-gaap:CommonStockMember
2025-04-01
2025-06-30
0001065078
us-gaap:AdditionalPaidInCapitalMember
2025-04-01
2025-06-30
0001065078
us-gaap:RetainedEarningsMember
2025-04-01
2025-06-30
0001065078
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001065078
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001065078
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001065078
2024-01-01
2024-03-31
0001065078
us-gaap:CommonStockMember
2024-04-01
2024-06-30
0001065078
us-gaap:AdditionalPaidInCapitalMember
2024-04-01
2024-06-30
0001065078
us-gaap:RetainedEarningsMember
2024-04-01
2024-06-30
0001065078
us-gaap:CommonStockMember
2025-06-30
0001065078
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0001065078
us-gaap:RetainedEarningsMember
2025-06-30
0001065078
us-gaap:CommonStockMember
2024-06-30
0001065078
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001065078
us-gaap:RetainedEarningsMember
2024-06-30
0001065078
2024-06-30
0001065078
nssi:ILiADBiotechnologiesLLCMember
2025-06-30
0001065078
nssi:LitigationSettlementsMember
2025-01-01
2025-06-30
0001065078
nssi:LitigationSettlementsMember
2024-01-01
2024-06-30
0001065078
nssi:LitigationSettlementsMember
2025-04-01
2025-06-30
0001065078
nssi:LitigationSettlementsMember
2024-04-01
2024-06-30
0001065078
srt:MinimumMember
2025-06-30
0001065078
srt:MaximumMember
2025-06-30
0001065078
srt:MinimumMember
2025-01-01
2025-06-30
0001065078
srt:MaximumMember
2025-01-01
2025-06-30
0001065078
nssi:StockIncentivePlan2022Member
2025-06-30
0001065078
nssi:StockIncentivePlan2013Member
2025-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2025-04-01
2025-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2024-04-01
2024-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2025-01-01
2025-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2024-01-01
2024-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2025-06-30
0001065078
us-gaap:RestrictedStockUnitsRSUMember
2024-12-31
0001065078
nssi:CostBasisMember
2025-06-30
0001065078
nssi:GrossUnrealizedGainsMember
2025-06-30
0001065078
nssi:GrossUnrealizedLossesMember
2025-06-30
0001065078
nssi:FairValueMember
2025-06-30
0001065078
nssi:CostBasisMember
2024-12-31
0001065078
nssi:GrossUnrealizedGainsMember
2024-12-31
0001065078
nssi:GrossUnrealizedLossesMember
2024-12-31
0001065078
nssi:FairValueMember
2024-12-31
0001065078
2025-03-01
2025-03-31
0001065078
nssi:OfficeSpaceMember
2025-01-01
2025-06-30
0001065078
srt:ChiefExecutiveOfficerMember
nssi:NewEmploymentAgreementMember
2022-03-01
2022-03-22
0001065078
2022-03-01
2022-03-22
0001065078
srt:ChiefExecutiveOfficerMember
2022-03-01
2022-03-22
0001065078
2023-01-01
2024-12-31
0001065078
nssi:IliadMember
2025-06-30
0001065078
nssi:IliadMember
nssi:ClassCUnitsMember
2025-06-30
0001065078
nssi:IliadMember
nssi:ClassCUnitsMember
2025-01-01
2025-06-30
0001065078
nssi:IliadMember
2025-04-01
2025-06-30
0001065078
nssi:IliadMember
2024-04-01
2024-06-30
0001065078
nssi:IliadMember
2025-01-01
2025-06-30
0001065078
nssi:IliadMember
2024-01-01
2024-06-30
0001065078
2024-01-01
2024-12-31
0001065078
2024-10-01
2025-03-31
0001065078
2023-10-01
2024-03-31
0001065078
2023-06-13
0001065078
2012-05-01
2025-06-30
0001065078
2022-08-01
2022-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
nssi:Integer
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_________________
FORM
10-Q
_________________
☒ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended June 30, 2025 |
|
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from __________ to__________ |
|
Commission
File Number 1-15288
NETWORK-1 TECHNOLOGIES, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware |
|
11-3027591 |
(State
or other jurisdiction of
incorporation or
organization) |
|
(I.R.S.
Employer
Identification
No.) |
|
|
|
65 Locust Avenue, Third Floor
New Canaan, Connecticut
|
|
06840 |
(Address of principal
executive offices) |
|
(Zip Code) |
203-920-1055
(Registrant’s
Telephone Number)
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
symbol |
Name
of each exchange on which registered |
Common
Stock, par value $0.01 per share
|
NTIP |
NYSE American
|
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§223.405) of this chapter during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
☐ |
|
Accelerated filer
☐ |
|
|
|
Non-accelerated filer ☐ |
Smaller reporting Company ☒ |
|
|
|
|
Emerging growth Company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of the registrant’s common stock, $.01 par
value per share, outstanding as of August 4, 2025 was 22,792,841.
NETWORK-1
TECHNOLOGIES, INC.
Form
10-Q Index
|
|
|
|
Page
No. |
PART
I. |
Financial
Information |
|
|
|
|
|
|
|
|
Item 1. |
Condensed Consolidated Financial Statements
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024
|
|
|
4 |
|
|
|
|
|
|
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited) |
|
|
5 |
|
|
|
|
|
|
Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 (unaudited) |
|
|
6 |
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited)
|
|
|
7 |
|
|
|
|
|
|
Notes to Unaudited Condensed Consolidated Financial Statements |
|
|
8 |
|
|
|
|
|
Item 2. |
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
|
|
21 |
|
|
|
|
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
|
|
26 |
|
|
|
|
|
Item 4. |
Controls and Procedures |
|
|
26 |
|
|
|
|
|
|
|
|
|
|
PART
II. |
Other
Information |
|
|
|
|
|
|
|
|
Item 1. |
Legal Proceedings |
|
|
27 |
|
|
|
|
|
Item 1A. |
Risk Factors |
|
|
27 |
|
|
|
|
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
|
|
27 |
|
|
|
|
|
Item 3. |
Defaults Upon Senior Securities |
|
|
28 |
|
|
|
|
|
Item 5. |
Other Information |
|
|
28 |
|
|
|
|
|
Item 6. |
Exhibits |
|
|
29 |
|
|
|
|
|
Signatures |
|
|
|
30 |
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions
that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such
forward-looking statements. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements include any expectation of earnings, revenue or other financial items; any statements
of the plans, strategies and objectives of management for future operations; factors that may affect our operating results; statements
related to future performance and other matters that do not relate strictly to historical facts or statements of assumptions underlying
any of the foregoing. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,”
“believe,” “can,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “will,” “plan,” “project,” “seek,” “should,”
“target,” “would,” and similar expressions or variations intended to identify forward-looking statements. These
statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking
statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain
events to differ materially from future results expressed or implied by such forward-looking statements. Except as required by law, we
undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Factors that could cause or contribute to such differences include various risks and uncertainties described below and elsewhere in this
Quarterly Report on Form 10-Q as well as in our Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the SEC on
February 28, 2025). Furthermore, such forward-looking statements speak only as of the date of this report. Such risks and uncertainties
include, but are not limited to, the following:
| • | our
uncertain revenue from licensing our intellectual property; |
| • | uncertainty
of the outcome of our pending litigations; |
| • | our
ability to achieve future revenue from our patent portfolios; |
| • | our
ability to protect our patents; |
| • | our
ability to execute our strategy to acquire or make investments in high quality patents with
significant licensing opportunities; |
| • | our
ability to enter into strategic relationships with third parties to license or otherwise
monetize their intellectual property; |
| • | our
ability to achieve a return on our investment in ILiAD Biotechnologies, LLC; |
| • | our
ability to continue to acquire additional intellectual property; |
| • | uncertainty
as to whether cash dividends will continue to be paid; |
| • | variations
in our quarterly and annual operating results; |
| • | the
risk that we may be determined to be a personal holding company in 2025 or future years which
may result in our issuing a special cash dividend to our stockholders to the extent we have
undistributed personal holding company income resulting in less cash available for our operations
and strategic transactions; and |
| • | legislative,
regulatory and competitive developments. |
Item
1. Condensed Consolidated Financial Statements
NETWORK-1
TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
| |
| | |
| |
| |
June 30, 2025 | | |
December 31, 2024 | |
ASSETS | |
(Unaudited) | | |
| |
CURRENT ASSETS: | |
| | |
| |
Cash and cash equivalents | |
$ | 13,424,000 | | |
$ | 13,145,000 | |
Marketable securities, at fair value | |
| 25,061,000 | | |
| 27,455,000 | |
Other current assets | |
| 180,000 | | |
| 232,000 | |
TOTAL CURRENT
ASSETS | |
| 38,665,000 | | |
| 40,832,000 | |
OTHER ASSETS: | |
| | | |
| | |
Patents, net of accumulated amortization | |
| 1,552,000 | | |
| 1,205,000 | |
Equity investment | |
| 2,596,000 | | |
| 3,337,000 | |
Operating leases right-of-use asset | |
| — | | |
| 27,000 | |
Security deposit | |
| 13,000 | | |
| 13,000 | |
Total Other Assets | |
| 4,161,000 | | |
| 4,582,000 | |
TOTAL ASSETS | |
$ | 42,826,000 | | |
$ | 45,414,000 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY: | |
| | | |
| | |
CURRENT LIABILITIES: | |
| | | |
| | |
Accounts payable | |
| 204,000 | | |
$ | 203,000 | |
Accrued payroll | |
| — | | |
| 292,000 | |
Other accrued expenses | |
| 173,000 | | |
| 247,000 | |
Operating lease obligations | |
| — | | |
| 24,000 | |
Total Current Liabilities | |
| 377,000 | | |
| 766,000 | |
LONG TERM LIABILITIES:
| |
| | | |
| | |
Deferred tax liability | |
| 188,000 | | |
| 337,000 | |
TOTAL LIABILITIES | |
| 565,000 | | |
| 1,103,000 | |
COMMITMENTS AND CONTINGENCIES (Note G) | |
| — | | |
| — | |
STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Preferred stock, $0.01 par value, authorized 10,000,000 shares; none issued and outstanding at June 30, 2025 and December 31, 2024 | |
| — | | |
| — | |
Common stock, $0.01 par value; authorized 50,000,000 shares; 22,844,798 and 22,961,619 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | |
| 228,000 | | |
| 229,000 | |
Additional paid-in capital | |
| 64,445,000 | | |
| 65,455,000 | |
Accumulated deficit | |
| (22,412,000 | ) | |
| (21,373,000 | ) |
| |
| | | |
| | |
TOTAL STOCKHOLDERS’ EQUITY | |
| 42,261,000 | | |
| 44,311,000 | |
TOTAL LIABILITIES
AND STOCKHOLDERS’ EQUITY | |
$ | 42,826,000 | | |
$ | 45,414,000 | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
NETWORK-1
TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
| | | |
| | | |
| | | |
| | |
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
| | |
| | |
| | |
| |
REVENUE | |
$ | — | | |
$ | 100,000 | | |
$ | 150,000 | | |
$ | 100,000 | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING EXPENSES: | |
| | | |
| | | |
| | | |
| | |
Costs of revenue | |
| — | | |
| 28,000 | | |
| 42,000 | | |
| 28,000 | |
Professional fees and related costs | |
| 164,000 | | |
| 147,000 | | |
| 285,000 | | |
| 366,000 | |
General and administrative | |
| 519,000 | | |
| 519,000 | | |
| 1,121,000 | | |
| 1,188,000 | |
Amortization of patents | |
| 37,000 | | |
| 30,000 | | |
| 67,000 | | |
| 60,000 | |
| |
| | | |
| | | |
| | | |
| | |
TOTAL OPERATING EXPENSES | |
| 720,000 | | |
| 724,000 | | |
| 1,515,000 | | |
| 1,642,000 | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING LOSS | |
| (720,000 | ) | |
| (624,000 | ) | |
| (1,365,000 | ) | |
| (1,542,000 | ) |
OTHER INCOME: | |
| | | |
| | | |
| | | |
| | |
Interest and dividend income, net | |
| 445,000 | | |
| 452,000 | | |
| 929,000 | | |
| 883,000 | |
Net realized and unrealized gain on marketable securities | |
| 22,000 | | |
| 54,000 | | |
| 171,000 | | |
| 102,000 | |
Total other income, net | |
| 467,000 | | |
| 506,000 | | |
| 1,100,000 | | |
| 985,000 | |
| |
| | | |
| | | |
| | | |
| | |
INCOME TAXES PROVISION: | |
| | | |
| | | |
| | | |
| | |
Current | |
| (31,000 | ) | |
| — | | |
| (31,000 | ) | |
| — | |
Deferred taxes, net | |
| (38,000 | ) | |
| (137,000 | ) | |
| (149,000 | ) | |
| (284,000 | ) |
Total income tax benefit | |
| (69,000 | ) | |
| (137,000 | ) | |
| (180,000 | ) | |
| (284,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
INCOME (LOSS) BEFORE SHARE OF NET LOSS OF EQUITY METHOD INVESTEE: | |
| (184,000 | ) | |
| 19,000 | | |
| (85,000 | ) | |
| (273,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
SHARE OF NET LOSS OF EQUITY METHOD INVESTEE
| |
| (279,000 | ) | |
| (677,000 | ) | |
| (741,000 | ) | |
| (1,305,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
NET LOSS | |
$ | (463,000 | ) | |
$ | (658,000 | ) | |
$ | (826,000 | ) | |
$ | (1,578,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.02 | ) | |
$ | (0.03 | ) | |
$ | (0.04 | ) | |
$ | (0.07 | ) |
Diluted | |
$ | (0.02 | ) | |
$ | (0.03 | ) | |
$ | (0.04 | ) | |
$ | (0.07 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 22,873,907 | | |
| 23,296,555 | | |
| 22,883,729 | | |
| 23,444,145 | |
Diluted | |
| 22,873,907 | | |
| 23,296,555 | | |
| 22,883,729 | | |
| 23,444,145 | |
| |
| | | |
| | | |
| | | |
| | |
Cash dividends declared per share | |
| — | | |
| — | | |
$ | 0.05 | | |
$ | 0.05 | |
| |
| | | |
| | | |
| | | |
| | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
NETWORK-1
TECHNOLOGIES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(UNAUDITED)
THREE
AND SIX MONTHS ENDED JUNE 30, 2025
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Common Stock | | |
| | | |
| | | |
| | |
| |
Shares | | |
Amount | | |
Additional Paid-in
Capital | | |
Accumulated
Deficit
| | |
Total
Stockholders’ Equity
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance – January 1, 2025 | |
| 22,961,619 | | |
$ | 229,000 | | |
$ | 65,455,000 | | |
$ | (21,373,000 | ) | |
$ | 44,311,000 | |
Dividends and dividend equivalents declared | |
| — | | |
| — | | |
| (1,171,000 | ) | |
| — | | |
| (1,171,000 | ) |
Stock-based compensation | |
| — | | |
| — | | |
| 81,000 | | |
| — | | |
| 81,000 | |
Vesting of restricted stock units | |
| 32,500 | | |
| — | | |
| — | | |
| — | | |
| — | |
Value of shares delivered to pay withholding taxes | |
| (5,348 | ) | |
| — | | |
| — | | |
| (7,000 | ) | |
| (7,000 | ) |
Treasury stock purchased and retired | |
| (106,662 | ) | |
| (1,000 | ) | |
| — | | |
| (149,000 | ) | |
| (150,000 | ) |
Net loss | |
| — | | |
| — | | |
| (363,000 | ) | |
| — | | |
| (363,000 | ) |
Balance – March 31, 2025 | |
| 22,882,109 | | |
| 228,000 | | |
| 64,365,000 | | |
| (21,892,000 | ) | |
| 42,701,000 | |
Stock-based compensation | |
| — | | |
| — | | |
| 80,000 | | |
| — | | |
| 80,000 | |
Vesting of restricted stock units | |
| 7,500 | | |
| — | | |
| — | | |
| — | | |
| — | |
Treasury stock purchased and retired | |
| (44,811 | ) | |
| — | | |
| — | | |
| (57,000 | ) | |
| (57,000 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (463,000 | ) | |
| (463,000 | ) |
Balance – June 30, 2025 | |
| 22,844,798 | | |
$ | 228,000 | | |
| 64,445,000 | | |
$ | (22,412,000 | ) | |
$ | 42,261,000 | |
THREE
AND SIX MONTHS ENDED JUNE 30, 2024
| |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Common Stock | | |
| | | |
| | | |
| | |
| |
Shares | | |
Amount | | |
Additional Paid-in
Capital | | |
Accumulated
Deficit
| | |
Total
Stockholders’ Equity
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance – January 1, 2024 | |
| 23,553,908 | | |
$ | 235,000 | | |
$ | 67,446,000 | | |
$ | (16,989,000 | ) | |
$ | 50,692,000 | |
Dividends and dividend equivalents declared | |
| — | | |
| — | | |
| — | | |
| (1,207,000 | ) | |
| (1,207,000 | ) |
Stock-based compensation | |
| — | | |
| — | | |
| 115,000 | | |
| — | | |
| 115,000 | |
Vesting of restricted stock units | |
| 111,250 | | |
| 1,000 | | |
| (1,000 | ) | |
| — | | |
| — | |
Value of shares delivered to pay withholding taxes | |
| (28,853 | ) | |
| — | | |
| — | | |
| (61,000 | ) | |
| (61,000 | ) |
Treasury stock purchased and retired | |
| (83,744 | ) | |
| (1,000 | ) | |
| — | | |
| (185,000 | ) | |
| (186,000 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (920,000 | ) | |
| (920,000 | ) |
Balance – March 31, 2024 | |
| 23,552,561 | | |
$ | 235,000 | | |
$ | 67,560,000 | | |
$ | (19,362,000 | ) | |
$ | 48,433,000 | |
Stock-based compensation | |
| — | | |
| — | | |
| 95,000 | | |
| — | | |
| 95,000 | |
Vesting of restricted stock units | |
| 11,250 | | |
| 1,000 | | |
| (1,000 | ) | |
| — | | |
| — | |
Treasury stock purchased and retired | |
| (373,701 | ) | |
| (4,000 | ) | |
| — | | |
| (693,000 | ) | |
| (697,000 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (658,000 | ) | |
| (658,000 | ) |
Balance – June 30, 2024 | |
| 23,190,110 | | |
$ | 232,000 | | |
$ | 67,654,000 | | |
$ | (20,713,000 | ) | |
$ | 47,173,000 | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
NETWORK-1
TECHNOLOGIES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
| | | |
| | |
| |
Six Months Ended June 30, | |
| |
2025 | | |
2024 | |
| |
| | |
| |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net loss | |
$ | (826,000 | ) | |
$ | (1,578,000 | ) |
Adjustments to reconcile net loss to net cash | |
| | | |
| | |
used in operating activities: | |
| | | |
| | |
Amortization of patents | |
| 67,000 | | |
| 60,000 | |
Stock-based compensation | |
| 161,000 | | |
| 210,000 | |
Loss allocated from equity method investment | |
| 741,000 | | |
| 1,305,000 | |
Unrealized (gain) loss on marketable securities | |
| (170,000 | ) | |
| 52,000 | |
Deferred tax benefit | |
| (149,000 | ) | |
| (284,000 | ) |
Amortization of operating leases – right of use assets | |
| 27,000 | | |
| 32,000 | |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Other current assets | |
| 52,000 | | |
| 24,000 | |
Accounts payable | |
| 1,000 | | |
| 81,000 | |
Operating lease obligations | |
| (24,000 | ) | |
| (41,000 | ) |
Accrued expenses | |
| (382,000 | ) | |
| (521,000 | ) |
NET CASH USED IN OPERATING ACTIVITIES | |
| (502,000 | ) | |
| (660,000 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Sales of marketable securities | |
| 7,554,000 | | |
| 12,852,000 | |
Acquisitions of patents | |
| (414,000 | ) | |
| — | |
| |
| | | |
| | |
NET CASH PROVIDED BY INVESTING ACTIVITIES | |
| 2,150,000 | | |
| 5,859,000 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Cash dividends paid | |
| (1,155,000 | ) | |
| (1,212,000 | ) |
Value of shares delivered to fund payment of withholding taxes | |
| (7,000 | ) | |
| (61,000 | ) |
Repurchases of common stock, inclusive of commissions | |
| (207,000 | ) | |
| (883,000 | ) |
| |
| | | |
| | |
NET CASH USED IN FINANCING ACTIVITIES: | |
| (1,369,000 | ) | |
| (2,156,000 | ) |
| |
| | | |
| | |
NET INCREASE IN CASH AND CASH EQUIVALENTS | |
| 279,000 | | |
| 3,043,000 | |
| |
| | | |
| | |
CASH AND CASH EQUIVALENTS, beginning of period | |
| 13,145,000 | | |
| 16,896,000 | |
| |
| | | |
| | |
CASH AND CASH EQUIVALENTS, end of period | |
$ | 13,424,000 | | |
$ | 19,939,000 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |
| | | |
| | |
Cash paid during the period for: | |
| | | |
| | |
Interest | |
$ | — | | |
$ | — | |
Income taxes | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
NON-CASH FINANCING ACTIVITIES | |
| | | |
| | |
Accrued dividend rights on restricted stock units | |
$ | 27,000 | | |
$ | 32,000 | |
Right of use asset and lease liability | |
$ | — | | |
$ | 75,000 | |
| |
| | | |
| | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
NETWORK-1
TECHNOLOGIES, INC.
Notes
to Unaudited Condensed Consolidated Financial Statements
NOTE
A – BASIS OF PRESENTATION AND NATURE OF BUSINESS
[1]
BASIS OF PRESENTATION
The
accompanying condensed consolidated financial statements are unaudited, but, in the opinion of the management of Network-1 Technologies,
Inc. (the “Company”), contain all adjustments consisting only of normal recurring items which the Company considers necessary
for the fair presentation of the Company’s financial position as of June 30, 2025, and the results of its operations and its changes
in stockholders’ equity for the three and six month periods ended June 30, 2025 and June 30, 2024, and the statement of cash flows
for the six months ended June 30, 2025 and June 30, 2024. The unaudited condensed consolidated financial statements included herein
have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim
financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, certain information and footnote disclosures
normally included in the consolidated financial statements prepared in accordance with U.S. GAAP may have been omitted pursuant to such
rules and regulations, although management believes that the disclosures are adequate to make the information presented not misleading.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February 28, 2025. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative
of the results of operations to be expected for the full year.
The
accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries,
Mirror Worlds Technologies, LLC and HFT Solutions, LLC. All intercompany balances and transactions have been eliminated in consolidation.
[2]
BUSINESS
The
Company is engaged in the development, licensing and protection of its intellectual property assets. The Company presently owns one-hundred
fifteen (115) U.S. patents, fifty-four (54) of which have expired, and seventeen (17) international patents related to (i) the M2M/IoT
patent portfolio (the “M2M/IoT Patent Portfolio”) relating to, among other things, enabling technology for authenticating
and using eSIM (embedded Subscriber Identification Module) technology in Internet of Things (“IoT”), Machine-to-Machine,
and other mobile devices, including smartphones, tablets and computers, as well as automobiles; (ii) the HFT patent portfolio (the “HFT
Patent Portfolio”) covering certain advanced technologies relating to high frequency trading, which inventions specifically address
technological problems associated with speed and latency and provide critical latency gains in trading systems where the difference between
success and failure may be measured in nanoseconds; (iii) the Cox patent portfolio (the “Cox Patent Portfolio”) relating
to enabling technology for identifying media content on the Internet and taking further actions to be performed after such identification;
(iv) the smart home patent portfolio (the “Smart Home Patent Portfolio”) relating to, among other things, the enabling technology
to support the interoperability of smart home IoT devices; (v) the Mirror Worlds patent portfolio (the “Mirror Worlds Patent Portfolio”)
relating to foundational technologies that enable unified search and indexing, displaying and archiving of documents in a computer system;
and (vi) the remote power patent (the “Remote Power Patent”) covering delivery of Power over Ethernet (PoE) cables for the
purpose of remotely powering network devices, such as wireless access ports, IP phones and network based cameras.
NOTE
A – BASIS OF PRESENTATION AND NATURE OF BUSINESS (continued)
The
Company’s current strategy includes continuing to pursue licensing opportunities for its patent portfolios. In addition, the Company
reviews opportunities to acquire or license additional intellectual property as well as other strategic alternatives. The Company’s
patent acquisition and development strategy is to focus on acquiring high quality patents which management believes have the potential
to generate significant licensing opportunities as the Company has achieved with respect to its Remote Power Patent and Mirror Worlds
Patent Portfolio. In addition, the Company may also enter into strategic relationships with third parties to develop, commercialize,
license or otherwise monetize their intellectual property.
The
Company has also made equity investments totaling $7,000,000 in ILiAD Biotechnologies, LLC (“ILiAD”), a clinical stage biotechnology
company (see Note J hereof).
NOTE
B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
[1] Use of Estimates and Assumptions
The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. The significant estimates and assumptions made in the preparation of the Company’s unaudited condensed consolidated financial
statements include costs related to the Company’s assertion of litigation, valuation of the Company’s patent portfolios,
stock-based compensation, the recoverability of deferred tax assets and the carrying value of the Company’s equity method investments.
Actual results could be materially different from those estimates upon which the carrying values were based.
Certain
amounts recorded to reflect the Company’s share of income or losses of its equity method investee, accounted for under the equity
method, are based on estimates and the unaudited results of operations of the equity method investee and may require adjustment in the
future when the audit of the equity method investee is complete. The Company reports its share of the results of its equity method investee
on a one quarter lag basis.
[2]
Revenue Recognition
Under
ASC 606, revenue is recognized when the Company completes the licensing of its intellectual property to its licensees, obtains a final
judgment awarding damages (after appeals have been exhausted) or enters into a litigation settlement agreement involving its patents.
With respect to licensing its intellectual property, obtaining a final judgment or entering into a litigation settlement agreement, revenue
is recognized in an amount that reflects the consideration the Company expects to be entitled to in exchange for licensing its intellectual
property, obtaining a final judgment or in a settlement of the litigation.
The
Company determines revenue recognition through the following steps:
| • | identification
of the license agreement, the final judgment or the litigation settlement agreement; |
| • | identification
of the performance obligations in the license agreement, the final judgment or the litigation
settlement agreement; |
| • | determination
of the consideration for the license, final judgment or settlement; |
| • | allocation
of the transaction price to the performance obligations in the contract; and |
| • | recognition
of revenue when the Company satisfies its performance obligations. |
NOTE
B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Revenue
disaggregated by source is as follows:
Schedule of revenue disaggregated | |
| | | |
| | | |
| | | |
| | |
| |
Six Months Ended
June 30, | | |
Three Months Ended
June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Litigation settlements | |
$ | 150,000 | | |
$ | 100,000 | | |
$ | — | | |
$ | 100,000 | |
Total Revenue | |
$ | 150,000 | | |
$ | 100,000 | | |
$ | — | | |
$ | 100,000 | |
Revenue
from the Company’s patent licensing and enforcement business is typically generated from negotiated license agreements or settlement
agreements as a result of litigation involving the Company’s patents. The timing and amount of revenue recognized from each licensee
or such settlement agreement depends upon a variety of factors, including the terms of each agreement and the nature of the obligations
of the parties. These agreements may include, but not be limited to, elements related to past infringement liabilities, non-refundable
upfront license fees, and ongoing royalties on licensed products sold by the licensee. Generally, in the event of a litigation settlement
related to the Company’s assertion of patent infringement involving its intellectual property, defendants may either pay (i) a
non-refundable lump sum payment for a non-exclusive fully-paid license, (ii) a non-refundable lump sum payment (license initiation fee)
together with an ongoing obligation to pay quarterly or monthly royalties to the Company for the life of the licensed patent, or (iii)
a lump sum settlement payment with respect to litigation involving the Company’s expired patents.
Fully-paid
licenses provide for a non-refundable up-front payment for which the Company has no future obligations or performance requirements, revenue
is generally recognized when the Company has obtained the signed license agreement, all performance obligations have been substantially
performed, amounts are fixed and determinable, and collectability is reasonably assured. Revenue from fully-paid licenses may consist
of one or more installments. The timing and amount of revenue recognized from each licensee depends upon a number of factors including
the specific terms of each agreement and the nature of the deliverables and obligations.
[3]
Equity Method Investments
Equity
method investments are equity securities in entities the Company does not control but over which it has the ability to exercise significant
influence. These investments are accounted for under the equity method of accounting in accordance with ASC 323, Investments —
Equity Method and Joint Ventures (see Note J hereof). Equity method investments are measured at cost minus impairment,
if any, plus or minus the Company’s share of an investee’s income or loss. The Company’s proportionate share of the
income or loss from equity method investments is recognized on a one-quarter lag. When the Company’s carrying value in an equity
method investment is reduced to zero, no further losses are recorded in the Company’s financial statements unless the Company has
guaranteed obligations of the investee company or has committed additional funding. When the investee company subsequently reports income,
the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
NOTE
B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Income
Taxes
The
Company accounts for income taxes in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 740, Income Taxes (ASC 740), which requires the Company to use the assets and liability method of accounting for income
taxes. Under the assets and liability method, deferred income taxes are recognized for the tax consequences of temporary(timing) differences
by applying enacted statutory tax rates applicable to future years to differences between financial statement carrying amounts and the
tax bases of existing assets and liabilities and operating loss and tax credit carry forwards. Under this accounting standard, the effect
on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. As of
June 30, 2025, the Company had total deferred tax assets generated from its activities of $1,671,000. The Company’s deferred tax
assets were offset by a valuation allowance of $1,671,000 as it was determined that it is more likely than not that certain deferred
tax assets will not be realized. As of June 30, 2025, the Company also had a deferred tax liability of $188,000.
The
personal holding company (“PHC”) rules under the Internal Revenue Code impose a 20% tax on a PHC’s undistributed personal
holding company income (“UPHCI”), which means, in general, taxable income subject to certain adjustments and reduced by certain
distributions to shareholders. For a corporation to be classified as a PHC, it must satisfy two tests: (i) that more than 50% in value
of its outstanding shares must be owned directly or indirectly by five or fewer individuals at any time during the second half of the
year (after applying constructive ownership rules to attribute stock owned by entities to their beneficial owners and among certain family
members and other related parties) (the “Ownership Test”) and (ii) at least 60% of its adjusted ordinary gross income for
a taxable year consists of dividends, interest, royalties, annuities and rents (the “Income Test”). As of July 15, 2025,
based on available information concerning the Company’s shareholder ownership, the Company did not satisfy the Ownership Test.
However, the Company may subsequently be determined to be a PHC in 2025 or in future years if it satisfies both the Ownership Test and
Income Test. If the Company were to become a PHC in 2025 or any future year, it would be subject to the 20% tax on its UPHCI. In such
event, the Company may issue a special cash dividend to its shareholders in an amount equal to the UPHCI rather than incur the 20% tax.
ASC
740-10, Accounting for Uncertainty in Income Taxes, defines uncertainty in income taxes and the evaluation of a tax position as
a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination,
including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure
a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements.
A tax position is measured at the largest amount of benefit that is greater than 50 percent likelihood of being realized upon ultimate
settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first
subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria
should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. The Company had no
uncertain tax positions as of June 30, 2025.
The
Company recognizes interest and penalties, if any, related to income tax in the income tax provision in the unaudited condensed consolidated
statements of operations and comprehensive loss.
NOTE
B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
U.S.
federal, state and local income tax returns prior to 2021 are not subject to examination by any applicable tax authorities, except that
tax authorities could challenge returns (only under certain circumstances) for earlier years to the extent they generated loss carry-forwards
that are available for those future years.
[5]
Segment Reporting
The
Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”)
reviews and assesses performance. The Company’s Chief Executive Officer is the CODM. The primary financial measures used by the
CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). Such measures are used to evaluate
the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Net loss and Operating
loss are disclosed in the consolidated statements of operations and comprehensive loss. Segment expenses and other segment items are
provided to the CODM on the same basis as disclosed in the consolidated statements of operations and comprehensive loss. The Company
has a single reporting segment.
[6]
Recent Accounting Pronouncements
Disaggregation
of Income Statement Expenses
In
November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income
Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses. The ASU requires additional information about specific expenses in certain notes to the Consolidated Financial Statements.
The guidance will be effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December
15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine
its impact on the Company's disclosures.
Income
Tax Disclosure
In
December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 requires disaggregated information
about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirements
will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the
option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating ASU 2023-09 to determine
its impact on the Company's disclosures.
NOTE
C – PATENTS
The
Company’s intangible assets at June 30, 2025, include patents with estimated remaining economic useful lives ranging from 8 to
15 years. For all periods presented, all of the Company’s patents were subject to amortization. The gross carrying amounts
and accumulated amortization related to acquired intangible assets as of June 30, 2025 and December 31, 2024 were as follows:
Schedule of patent | |
| | | |
| | |
| |
June
30, 2025 | | |
December
31, 2024 | |
| |
| | | |
| | |
Gross carrying amount – patents | |
$ | 8,887,000 | | |
$ | 8,473,000 | |
Accumulated amortization – patents | |
| (7,335,000 | ) | |
| (7,268,000 | ) |
Patents, net | |
$ | 1,552,000 | | |
$ | 1,205,000 | |
Amortization
expense for the three months ended June 30, 2025 and 2024 was $37,000 and $30,000, respectively. Amortization expense for the six months
ended June 30, 2025 and 2024 was $67,000 and $60,000, respectively. Future amortization of intangible assets for the next five years
and thereafter is as follows:
Schedule of future amortization of intangible assets | | |
| | |
For the
Years Ended December 31, | |
2025
– remaining | | |
$ | 74,000 | |
2026 | | |
| 147,000 | |
2027 | | |
| 146,000 | |
2028 | | |
| 143,000 | |
2029 | | |
| 143,000 | |
Thereafter | | |
| 899,000 | |
Total | | |
$ | 1,552,000 | |
| | |
| | |
The
expiration dates of patents within the Company’s M2M/IoT Patent Portfolio range from September 2033 to May 2034. The expiration
dates within the Company’s HFT Patent Portfolio range from October 2039 to February 2040. The expiration dates of patents within
the Company’s Smart Home Patent Portfolio range from May 2039 to May 2040. All of the patents within the Company’s Mirror
Worlds Patent Portfolio, Cox Patent Portfolio and the Remote Power Patent have expired.
NOTE
D – STOCKHOLDERS’ EQUITY
Stock Incentive Plan
The
Company adopted the 2022 Stock Incentive Plan, (the “2022 Plan”), approved by its Board of Directors on July 25, 2022 and
its stockholders on September 20, 2022. The 2022 Plan provides for the grant of any or all of the following types of awards: (a) stock
options, (b) restricted stock, (c) deferred stock, (d) stock appreciation rights, and (e) other stock-based awards including restricted
stock units.
As
of June 30, 2025, there were 92,500 shares of common stock subject to outstanding awards under the 2022 Plan and 2,040,000 shares of
common stock available for issuance under the 2022 Plan. In addition, there were 425,000 shares of common stock subject to outstanding
awards under the 2013 Plan.
NOTE
D – STOCKHOLDERS’ EQUITY (CONTINUED)
Restricted
Stock Units
A
summary of restricted stock unit activity for the six months ended June 30, 2025 is as follows (each restricted stock unit issued by
the Company represents the right to receive one share of the Company’s common stock):
Schedule of stock option activity | |
| | | |
| | |
| |
Number of Shares | | |
Weighted-Average
Grant Date Fair Value | |
Balance of restricted stock units outstanding at December 31, 2024 | |
| 487,500 | | |
$ | 1.66 | |
Grants of restricted stock units | |
| 70,000 | | |
| 1.41 | |
Vested restricted stock units | |
| (40,000 | ) | |
| (1.90 | ) |
Balance of restricted stock units outstanding at June 30, 2025 | |
| 517,500 | | |
$ | 1.61 | |
Restricted
stock unit compensation expense was $80,000 and $95,000 for the three months ended June 30, 2025 and 2024, respectively. Restricted stock
unit compensation expense was $161,000 and $210,000 for the six months ended June 30, 2025 and 2024, respectively. Stock-based compensation
expense is included in general and administrative expenses in the unaudited condensed consolidated statements of operations.
The
Company had an aggregate of $198,000 of unrecognized restricted stock unit compensation as of June 30, 2025 to be expensed over a weighted
average period of approximately one year.
All
of the Company’s outstanding (unvested) restricted stock units have dividend equivalent rights. During the three months ended June
30, 2025 and 2024, the Company paid a total of $11,000 and $2,000, respectively of such dividend equivalent rights. During the six months
ended June 30, 2025 and 2024, the Company paid a total of $11,000 and $37,000, respectively of such dividend equivalent rights. As of
June 30, 2025 and December 31, 2024, there was $137,000 and $121,000, respectively, accrued for dividend equivalent rights which
were included in other accrued expenses.
NOTE
E – LOSS PER SHARE
Basic
loss per share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period.
Diluted per share data includes the dilutive effects of restricted stock units. Potentially dilutive shares of 517,500 and 535,000 at
June 30, 2025 and 2024, respectively, consisted of outstanding restricted stock units. However, since the Company generated a net loss
for the six months ended June 30, 2025 and 2024, all potentially dilutive shares were not reflected in diluted net loss per share because
the impact of such instruments was anti-dilutive.
Computations
of basic and diluted weighted average common shares outstanding were as follows:
Schedule of basic and diluted weighted average common shares outstanding | |
| | | |
| | | |
| | | |
| | |
| |
Six Months Ended June 30, | | |
Three Months Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average common shares outstanding – basic | |
| 22,883,729 | | |
| 23,444,145 | | |
| 22,873,907 | | |
| 23,296,555 | |
Dilutive effect of restricted stock units and stock options | |
| — | | |
| — | | |
| — | | |
| — | |
Weighted-average common shares outstanding – diluted | |
| 22,883,729 | | |
| 23,444,145 | | |
| 22,873,907 | | |
| 23,296,555 | |
Restricted stock units excluded from the computation of diluted loss per share because the effect of inclusion would have been anti-dilutive | |
| 517,500 | | |
| 535,000 | | |
| 517,500 | | |
| 535,000 | |
NOTE
F – MARKETABLE SECURITIES
Marketable
securities as of June 30, 2025 and December 31, 2024 were composed of the following:
Schedule of marketable
securities | |
| | | |
| | | |
| | | |
| | |
| |
June 30, 2025 | |
| |
Cost
Basis | | |
Unrealized
Gains | | |
Unrealized
Losses | | |
Fair
Value | |
Certificates of deposit | |
$ | 752,000 | | |
$ | 7,000 | | |
$ | — | | |
$ | 759,000 | |
Government securities | |
| 12,844,000 | | |
| 78,000 | | |
| (40,000 | ) | |
| 12,882,000 | |
Fixed income mutual funds | |
| 9,698,000 | | |
| 233,000 | | |
| — | | |
| 9,931,000 | |
Corporate bonds | |
| 1,490,000 | | |
| — | | |
| (1,000 | ) | |
| 1,489,000 | |
Total marketable securities | |
$ | 24,874,000 | | |
$ | 318,000 | | |
$ | (41,000 | ) | |
$ | 25,061,000 | |
| |
December 31, 2024 | |
| |
Cost
Basis | | |
Gross
Unrealized
Gains | | |
Gross
Unrealized
Losses | | |
Fair
Value | |
Government securities | |
$ | 16,470,000 | | |
$ | 63,000 | | |
$ | (71,000 | ) | |
$ | 16,462,000 | |
Fixed income mutual funds | |
| 9,630,000 | | |
| 132,000 | | |
| (30,000 | ) | |
| 9,732,000 | |
Certificates of deposit | |
| 752,000 | | |
| 9,000 | | |
| — | | |
| 761,000 | |
Corporate bonds and notes | |
| 496,000 | | |
| 4,000 | | |
| — | | |
| 500,000 | |
Total marketable securities | |
$ | 27,348,000 | | |
$ | 208,000 | | |
$ | (101,000 | ) | |
$ | 27,455,000 | |
| |
| | | |
| | | |
| | | |
| | |
The
Company’s marketable securities are classified within Level 1 of the fair value hierarchy because they are valued using quoted
market prices in an active market.
NOTE
G – COMMITMENTS AND CONTINGENCIES
[1]
Legal Fees
The
Company engages law firms with respect to its patent litigation on a full contingency basis ranging from 15-40% (with certain exceptions)
of the net recovery (after deduction of expenses) depending on the stage of the proceeding in which the result (settlement or judgment)
is achieved. The Company is responsible for all or a portion of the expenses incurred with respect to such litigation. With respect to
proceedings at the U.S Patent and Trademark Office, the Company engages law firms on a fixed fee basis.
[2]
Patent Acquisition
On
March 31, 2025, the Company acquired its Smart Home Patent Portfolio from IoT and M2M Technologies, LLC for a purchase price of $400,000.
In addition, the Company is obligated to pay the seller an additional $50,000 upon certain events. The Company is also obligated to pay
the seller 12.5% of the first $100 million of net proceeds (after the deduction of expenses) and 5% of the net proceeds in excess of
$100 million from Monetization Activities (as defined) related to the patent portfolio.
In
connection with the Company’s acquisition of its HFT Patent Portfolio in March 2022, the Company paid the seller $500,000 in cash
and has an obligation to pay $375,000 of the Company’s common stock (up to a maximum of 375,000 shares) upon achieving certain
milestones with respect to the patent portfolio. The Company also has an additional obligation to pay the seller 15% of the first $50
million of net proceeds (after deduction of expenses) generated by the patent portfolio and 17.5% of net proceeds greater than $50 million.
In
connection with the Company’s acquisition of its Cox Patent Portfolio in February 2013, the Company is obligated to pay Dr. Cox
12.5% of the net proceeds (after deduction of expenses) generated by the Company from licensing, sale or enforcement of the patent portfolio.
In
connection with the Company’s acquisition of its M2M/IoT Patent Portfolio in December 2017, the Company is obligated to pay the
seller 14% of the first $100 million of net proceeds (after deduction of expenses) and 5% of net proceeds greater than $100 million from
Monetization Activities (as defined) related to the patent portfolio. In addition, the seller will be entitled to receive from the Company
$250,000 of additional consideration upon the occurrence of certain future events related to the patent portfolio.
[3]
Leases
The
Company had one operating lease for its principal office space in New Canaan, Connecticut that was to expire on April 30, 2025. On April
23, 2025, the Company extended its lease for one year to April 30, 2026 with an option to renew for two additional years. The Company
accounts for the extension as a short-term lease. The Company pays a base rent of $5,500 for such office space. The remaining lease term
as of June 30, 2025 was 10 months.
There
are no material residual guarantees associated with the Company’s lease and there are no significant restrictions or covenants
included in the Company’s lease agreement.
NOTE
G- COMMITMENTS AND CONTINGENCIES (CONTINUED)
Right
of use lease assets and related lease obligations for the Company’s operating lease and the short-term lease extension are recorded
in the unaudited condensed consolidated balance sheets as follows:
Schedule of right
of use lease assets and related lease obligations | |
| | | |
| | |
| |
As of
June 30, 2025 | | |
As
of December
31, 2024 | |
| |
| | | |
| | |
Operating lease right-of-use assets | |
$ | — | | |
$ | 27,000 | |
| |
| | | |
| | |
Operating lease obligations – current | |
$ | — | | |
$ | 24,000 | |
| |
| | | |
| | |
The
table below presents certain information related to the Company’s lease costs for the period ended:
Schedule of lease costs | |
| | | |
| | | |
| | | |
| | |
| |
Six Months Ended June 30, | | |
Three Months Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Operating lease cost | |
$ | 27,000 | | |
$ | 27,000 | | |
$ | 5,000 | | |
$ | 10,000 | |
Short-term lease cost | |
| 12,000 | | |
| — | | |
| 12,000 | | |
| — | |
Total | |
$ | 39,000 | | |
$ | 27,000 | | |
$ | 17,000 | | |
$ | 10,000 | |
NOTE–H
- EMPLOYMENT ARRANGEMENTS AND OTHER AGREEMENTS
On
March 22, 2022, the Company entered into an employment agreement (“Agreement”) with its Chairman and Chief Executive Officer,
pursuant to which he continues to serve as the Company’s Chairman and Chief Executive Officer for a four-year term (“Term”),
at an annual base salary of $535,000 which shall be increased by 3% per annum during the term of the Agreement. The Agreement established
an annual target bonus of $175,000 for the Chairman and Chief Executive Officer based upon performance.
Under
the terms of the Agreement (which terms are substantially the same as the prior employment agreement with the Chairman and Chief Executive
Officer), so long as the Chairman and Chief Executive Officer continues to serve as an executive officer of the Company, whether pursuant
to the Agreement or otherwise, the Chairman and Chief Executive Officer shall also receive incentive compensation in an amount equal
to 5% of the Company’s gross royalties or other payments from Licensing Activities (as defined) (without deduction of legal fees
or any other expenses) with respect to its Remote Power Patent and a 10% net interest (gross royalties and other payments after deduction
of all legal fees and litigation expenses related to licensing, enforcement and sale activities, but in no event shall he receive less
than 6.25% of the gross recovery) of the Company’s royalties and other payments relating to Licensing Activities with respect to
patents other than the Remote Power Patent (including all of the Company’s patent portfolios and its return on investment in ILiAD
Biotechnologies) (collectively, the “Incentive Compensation”). During the three months ended June 30, 2025 and 2024, the
Chairman and Chief Executive Officer earned Incentive Compensation of $0 and $5,000, respectively. During the six months ended
June 30, 2025 and 2024, the Chairman and Chief Executive Officer earned Incentive Compensation of $8,000 and $5,000, respectively.
NOTE
I – LEGAL PROCEEDINGS
[1]
On June 27, 2025, the Company commenced patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc.
(collectively, “Samsung”) in the United States District Court for the Eastern District of Texas, Marshall Division, for infringement
of certain patents within the Company’s M2M/ IoT Patent Portfolio. The lawsuit alleges that Samsung infringes the Company patents
by supporting certain eSIM (embedded Subscriber Identification Module) and 5G technologies in its mobile devices, including its Galaxy
smartphones, watches and tablets (the “Accused Products”). The Accused Products operate consistent with certain GSMA and
ETSI industry standards.
[2]
On December 24, 2024, the Company’s wholly-owned subsidiary, HFT Solutions, LLC, commenced patent litigations against Citadel Securities,
LLC (“Citadel”) and Jump Trading, LLC in the United States District Court for the Northern District of Illinois for infringement
of certain patents within our HFT Patent Portfolio. The HFT Patent Portfolio relates to, among other things, certain advanced technologies
relating to high frequency trading, which inventions specifically address technological problems associated with speed and latency
and provide critical latency gains in trading systems where the difference between success and failure may be measured in nanoseconds.
On April 7, 2025, Citadel filed a motion to dismiss under 35 U.S.C. 101, asserting that the asserted patents are directed to patent ineligible
subject matter.
[3]
On April 4, 2014 and December 3, 2014, the Company initiated litigation against Google Inc. (“Google”) and YouTube,
LLC (“YouTube”) in the U.S. District Court for the Southern District of New York for infringement of several of its patents
within its Cox Patent Portfolio acquired from Dr. Cox which relate to the identification of media content on the Internet. The lawsuit
alleges that Google and YouTube have infringed and continue to infringe certain of the Company’s patents by making, using, selling
and offering to sell unlicensed systems and related products and services, which include YouTube’s Content ID system. The litigations
against Google and YouTube were subject to court ordered stays which were in effect from July 2, 2015 until January 2, 2019
as a result of proceedings at the Patent Trial and Appeal Board (PTAB) and the appeals of PTAB Final Written Decisions to the U.S. Court
of Appeals for the Federal Circuit. Pursuant to a Joint Stipulation and Order Regarding Lifting of Stays, entered on January 2, 2019,
the parties agreed, among other things, that the stays with respect to the litigations were lifted. In January 2019, the two litigations
against Google and YouTube were consolidated. Discovery has been completed and the parties have each submitted summary judgment motions.
On April 24, 2024, the U.S. District Court for the Southern District of New York issued a judgment dismissing the Company’s patent
infringement claims finding that the asserted claims of two of the patents are invalid for indefiniteness and granting summary judgment
that the asserted claims of another asserted patent are not infringed by Google’s accused system. The Court’s ruling disposes
of all of the Company’s claims in the case. On May 14, 2024, the Company filed a notice of appeal to the U.S. Court of Appeals
for the Federal Circuit and the appeal is pending.
[4]
In October and November 2022, the Company initiated nine separate litigations against ten defendants for infringement of its Remote Power
Patent seeking monetary damages based upon reasonable royalties. The defendants in the litigations were Arista Networks, Inc., Honeywell
International Inc., Ubiquiti Inc., TP- Link USA Corporation, Hikvision USA, Inc., Panasonic Holdings Corporation and Panasonic Corporation
of North America, Antaira Technologies, LLC, and Dahua Technology USA.
NOTE
I - LEGAL PROCEEDINGS (CONTINUED)
During
2023 and 2024, the Company entered into settlement agreements for an aggregate of $2,701,000 with all of the defendants in the above
referenced litigations except for Ubiquiti Inc. On January 14, 2025, the U.S. District Court for the District of Delaware granted Ubiquiti’s
partial motion for summary judgment on indirect infringement. On February 13, 2025, the Court granted the parties’ joint motion
to dismiss the case.
During
the six months ended June 30, 2025, the Company received a conditional payment of $150,000
from a defendant as the terms of the conditional payment had
been satisfied and recorded as revenue in the unaudited condensed consolidated statements of operations.
NOTE
J – INVESTMENT
During
the period December 2018 through August 2022, the Company made aggregate investments of $7,000,000 in ILiAD Biotechnologies, LLC (“ILiAD”),
a privately held clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella
pertussis. ILiAD is focused on validating its proprietary intranasal vaccine, BPZE1, for the prevention of pertussis (whooping cough).
At June 30, 2025, the Company owned approximately 6.5% of the outstanding units of ILiAD on a non-fully diluted basis and 4.8% of the
outstanding units on a fully diluted basis (after giving effect to the exercise all outstanding options and warrants). In connection
with its initial investment, the Company’s Chairman and Chief Executive Officer obtained a seat on ILiAD’s Board of Managers
and receives the same compensation for service on the Board of Managers as other non-management Board members.
For
the three months ended June 30, 2025 and 2024, the Company recorded an allocated net loss from its equity method investment in ILiAD
of $279,000 and $677,000, respectively. For the six months ended June 30, 2025 and 2024, the Company recorded an allocable loss from
its equity method investment in ILiAD of $741,000 and $1,305,000. As of June 30, 2025 and December 31, 2024, the carrying value of the
Company’s equity method investment in ILiAD was $2,596,000 and $3,337,000, respectively.
The
following table provides certain summarized financial information for ILiAD (the equity method investee) for the periods presented and
has been compiled from ILiAD’s unaudited financial statements, reported on one quarter lag.
Schedule of financial information | |
| | | |
| | | |
| | | |
| | |
| |
Six Months Ended March 31, | | |
Three Months Ended March 31, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Loss from continuing operations | |
$ | (11,391,000 | ) | |
$ | (20,073,500 | ) | |
$ | (4,267,000 | ) | |
$ | (7,610,000 | ) |
Comprehensive loss | |
$ | (11,450,000 | ) | |
$ | (19,656,000 | ) | |
$ | (4,326,000 | ) | |
$ | (7,428,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
NOTE
K – STOCK REPURCHASES
On
June 17, 2025, the Board of Directors authorized an extension and increase of the Company’s share repurchase program (the
“Share Repurchase Program”) to repurchase up to $5,000,000
of common stock over the subsequent 24 month period. The common stock may be repurchased from time to time in open market
transactions or privately negotiated transactions at the Company’s discretion except for repurchases under the Company’s
10b5-1 plans. The timing and amount of the shares repurchased is determined by management, except for repurchases under the
Company’s 10b5-1 plans, based on its evaluation of market conditions and other factors. The Share Repurchase Program may be
increased, suspended or discontinued at any time. Since inception of the Share Repurchase Program through June 30, 2025, the Company
has repurchased an aggregate of 10,525,705
shares of its common stock at an aggregate cost of $20,185,549
(exclusive of commissions) or an average per share price of $1.92.
NOTE
K – STOCK REPURCHASES (CONTINUED)
During
the three months ended June 30, 2025, the Company repurchased an aggregate of 44,811 shares of its common stock at an aggregate cost
of $55,337 (exclusive of commissions ) or an average per share price of $1.23. During the six months ended June 30, 2025, the Company
repurchased an aggregate of 151,473 shares of its common stock at an aggregate cost of $202,194 (exclusive of commissions) or an average
per share price of $1.33.
On
June 30, 2025, the Company entered into a written trading plan (the “10b5-1 Plan”) under Rule 10b5-1 of the Securities Exchange
Act of 1934 (the “Exchange Act”). Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to
repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading black-outs or pursuant
to insider trading laws. Purchases under the 10b5-1 Plan may be made during the following periods: (1) beginning on July 10, 2025 until
two trading days after the Company issues a press release announcing its financial results for the quarter ended June 30, 2025, and (2)
beginning on October 1, 2025 until two trading days after the Company issues a press release announcing its financial results for the
quarter ended September 30. 2025. Under the 10b5-1 Plan, the Company’s third party broker may purchase up to 1,000,000 shares of
the Company’s common stock, subject to certain price, market, volume and timing constraints, in accordance with the terms of the
plan and subject to Rule 10b5-1 and Rule 10b-18 of the Exchange Act.
On
August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for,
among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations occurring
on or after January 1, 2023. The amount of the excise tax is generally 1% of the net fair market value of the net shares repurchased
(repurchases net of new share issuances) at the time of the repurchase. The excise tax applies in cases where the total value of if the
stock repurchased during the taxable year exceeds $1,000,000. At June 30, 2025 and 2024, the Company had not incurred such excise tax.
At
June 30, 2025, the dollar value of remaining shares that may be repurchased under the Share Repurchase Program was $4,994,853.
NOTE
L – CONCENTRATIONS OF CREDIT RISK
The
Company maintains cash and certificates of deposit in accounts at financial institutions. The accounts are insured by the Federal Deposit
Insurance Corporation (“FDIC”) up to $250,000 at each institution. At June 30, 2025, the Company had $8,000 of cash and certificates
of deposit in excess of the FDIC insured limit. The Company maintains cash equivalents in brokerage accounts at financial institutions.
At June 30, 2025, the Company had cash equivalents of $13,373,000 in these brokerage accounts.
NOTE
M – DIVIDEND POLICY
The
Company’s dividend policy consists of semi-annual cash dividends of $0.05 per share ($0.10 per share annually) anticipated to be
paid in March and September of each year. The Company has paid semi-annual cash dividends consistent with its policy. The Company’s
dividend policy undergoes a periodic review by the Board of Directors and is subject to change at any time depending upon the Company’s
earnings, financial requirements and other factors existing at the time.
ITEM
2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q.
OVERVIEW
Our
principal business is the development, licensing and protection of our intellectual property assets. We presently own one-hundred fifteen
(115) U.S. patents, fifty-four (54) of which have expired, and seventeen (17) international patents related to (i) the M2M/IoT patent
portfolio (the “M2M/IoT Patent Portfolio”) relating to, among other things, enabling technology for authenticating and using
eSIM (embedded Subscriber Identification Module) technology in Internet of Things (“IoT”)Machine-to-Machine, and other mobile
devices, including smartphones, tablets and computers, as well as automobiles; (ii) the HFT patent portfolio (the “HFT Patent Portfolio”)
covering certain advanced technologies relating to high frequency trading, which inventions specifically address technological problems
associated with speed and latency and provide critical latency gains in trading systems where the difference between success and failure
may be measured in nanoseconds; (iii) the Cox patent portfolio (the “Cox Patent Portfolio) relating to enabling technology for
identifying media content on the Internet and taking further actions to be performed after such identification; (iv) the smart home patent
portfolio (the “Smart Home Patent Portfolio”) relating to, among other things, the enabling technology to support the interoperability
of smart home IoT devices; (v) the Mirror Worlds patent portfolio (the “Mirror Worlds Patent Portfolio”) relating to foundational
technologies that enable unified search and indexing, displaying and archiving of documents in a computer system; and (vi) the remote
power patent (the “Remote Power Patent”) covering delivery of Power over Ethernet (PoE) cables for the purpose of remotely
powering network devices, such as wireless access ports, IP phones and network based cameras.
Although
fifty-four (54) of our U.S. patents have expired, we can assert expired patents against third parties but only for past damages up to
the patent expiration date. We currently have a pending appeal involving certain expired patents within our Cox Patent Portfolio and
our revenue for the six months ended June 30, 2025 related to a settlement payment received from litigation involving our expired Remote
Power Patent. (see Note I[4] to our unaudited condensed consolidated financial statements included herein).
At
June 30, 2025 our principal sources of liquidity consisted of cash and cash equivalents and marketable securities of $38,485,000 and
working capital of $38,288,000. Based on our cash position, we review opportunities to acquire additional intellectual property as well
as evaluate other strategic opportunities.
To
date we have invested $7,000,000 in ILiAD, a clinical stage biotechnology company with an exclusive license to seventy-seven (77) patents
(see Note J to our unaudited condensed consolidated financial statements included herein). Our investment continues to involve significant
risk and the outcome is uncertain.
We
have been dependent upon our Remote Power Patent for a significant portion of our revenue. Our Remote Power Patent has generated licensing
revenue in excess of $188,000,000 from May 2007 through June 30, 2025. We no longer receive licensing revenue for our Remote Power Patent
for any period subsequent to March 7, 2020 (the expiration date of the patent). All of our revenue for 2024 and for the six months ended
June 30, 2025 was from settlements involving our Remote Power Patent.
On
June 27, 2025, we commenced patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. (collectively,
“Samsung”) in the United States District Court for the Eastern District of Texas for infringement of certain patents within
our M2M/IoT Patent Portfolio. The lawsuit alleges that Samsung infringes our patents by supporting certain eSIM (embedded Subscriber
Identification Module) and 5G technologies in its mobile devices, including its Galaxy smartphones, watches and tablets (see Note I[1]
to our unaudited condensed consolidated financial statements included herein).
In
December 2024, we commenced patent infringement litigations against Citadel Securities, LLC and Jump Trading, LLC involving our HFT Patent
Portfolio (see Note I[2] to our unaudited condensed consolidated financial statements included herein).
In
addition, we have appealed the judgment of the District Court dismissing our litigation against Google and YouTube involving certain
patents within our Cox Patent Portfolio (see Note I[3] to our unaudited condensed consolidated financial statements included herein).
On
March 31, 2025, we acquired our Smart Home Patent Portfolio from IoT and M2M Technologies, LLC, relating to, among other things, enabling
technology to support the interoperability of smart home IoT devices. The patent portfolio currently consists of eight (8) U.S. patents
and one (1) international patent as well as eleven (11) U.S. pending patent applications and five (5) pending international patents (see
Note G[2] to our unaudited condensed consolidated financial statements included herein).
If
we are unable to successfully monetize our patent portfolios or achieve a successful outcome of our investment in ILiAD, our business,
financial condition and results of operations will be negatively impacted.
Our
current strategy includes continuing our licensing efforts with respect to our intellectual property assets and the monetization of our
patent portfolios. In addition, we continue to seek to acquire additional intellectual property assets to develop, commercialize, license
or otherwise monetize. Our strategy includes working with inventors and patent owners to assist in the development and monetization of
their patented technologies. We may also enter into strategic relationships with third parties to develop, commercialize, license or
otherwise monetize their intellectual property. Our patent acquisition and development strategy is to focus on acquiring high quality
patents which management believes have the potential to generate significant licensing opportunities as we have achieved with respect
to our Remote Power Patent and Mirror Worlds Patent Portfolio.
The
significant components of expenses, when revenue is recorded, that may impact our net income (loss) relate to contingent legal fees and
expenses related to our patent litigation (see Note G[1] to our unaudited condensed consolidated financial statements included herein)
and incentive compensation payable to our Chairman and Chief Executive Officer pursuant to his employment agreement (see Note H to our
unaudited condensed consolidated financial statements included herein). Both such components of expenses are based on a percentage of
the revenue received by us as a result of litigation or otherwise.
Our
annual and quarterly operating and financial results may fluctuate significantly from period to period as a result of a variety of factors
that are outside our control, including the timing and our ability to achieve successful outcomes of our patent litigation, our ability
and timing of consummating future license agreements for our intellectual property, and whether we will achieve a return on our investment
in ILiAD and the timing of any such return.
Our
future operating results may also be materially impacted by our ability to acquire high quality patents which management believes have
the potential to generate significant licensing opportunities. In the future, we may not be able to identify or consummate such patent
acquisitions or, if consummated, achieve significant licensing revenue with respect to such acquisitions.
In
2025 and future years we could be classified as a Personal Holding Company. If this is the case, we would be subject to a 20% tax on
the amount of any undistributed personal holding company income (as defined) for such year that we do not distribute to our shareholders
(see Note B[4] to our unaudited condensed consolidated financial statements included in this Quarterly Report).
RESULTS
OF OPERATIONS
Three
Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024
Revenue.
We had no revenue for the three months ended June 30, 2025 and $100,000 in revenue for the three months ended June 30, 2024 from a litigation
settlement involving our Remote Power Patent (See Note I[4] to our unaudited condensed consolidated financial statements included herein).
Income
Taxes. For the three months ended June 30, 2025, we realized a $31,000 current tax benefit related to a federal income tax refund,
as compared to no current tax expense for federal, state and local income taxes for the same period in 2024. We had a deferred tax benefit
of $38,000 and $137,000 for the three months ended June 30, 2025 and 2024, respectively. The decrease of $99,000 was caused primarily
by a decrease in the net losses of ILiAD recognized in 2025.
Share
of Net Losses of Equity Method Investee. We recognized $279,000 of net losses during the three month period ended June 30, 2025,
related to our equity share of ILiAD net losses, as compared to a recognized net loss of $677,000 for the three months ended June 30,
2024. We anticipate continuing to record our share of net losses from ILiAD.
Net
Loss. As a result of the foregoing, we realized a net loss of $463,000 or $0.02 per share basic and diluted for the three months
ended June 30, 2025, compared with a net loss of $658,000 or $0.03 per share basic and diluted for the three months ended June 30,
2024. The reduction in our net loss of $195,000 for the three months ended June 30, 2025, as compared to 2024, was primarily the result
of a decrease of $398,000 of our share of net losses of ILiAD, which offset the effect of decreases in revenue of $100,000, other income
of $39,000 and income tax benefits of $68,000.
Six
Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2024
Revenue.
We had revenue of $150,000 for the six months ended June 30, 2025 and $100,000 in revenue for the six months ended June 30, 2024. All
such revenue was from litigation settlements involving our Remote Power Patent (See Note I[4] to our unaudited condensed consolidated
financial statements included herein).
Operating
Expenses. Operating expenses for the six months ended June 30, 2025 were $1,515,000 as compared to $1,642,000 for the six months
ended June 30, 2024. The decrease in operating expenses of $127,000 was primarily as a result of lower professional fees and related
costs of $81,000 from decreased revenue from litigation settlements in 2025 and decreased general and administrative expenses of $67,000.
General
and administrative expenses were $1,121,000 for the six months ended June 30, 2025 as compared to $1,188,000 for the six months ended
June 30, 2024. The decrease in general and administrative expenses of $67,000 was primarily due to decreased stock-based compensation
of $49,000.
AGÕæÈ˹ٷ½ized
and Unrealized Gain on Marketable Securities. For the six months ended June 30, 2025, we recorded realized and unrealized gains on
marketable securities of $171,000, as compared to $102,000 for the six months ended June 30, 2024. The increase was largely due to the
timing of the maturities of fixed income investments.
Income
Taxes. For the six months ended June 30, 2025, we realized a $31,000 current tax benefit related to a federal income tax refund,
as compared to no current tax expense for federal, state and local income taxes for the same period in 2024. We had a deferred tax benefit
of $149,000 and $284,000 for the six months ended June 30, 2025 and 2024, respectively. The decrease of $135,000 in our deferred tax
benefit was primarily due to a decrease of $564,000 in our recognized net losses of our equity method investee for the six months ended
June 30, 2025.
Share
of Net Losses of Equity Method Investee. We recognized $741,000 of net losses during the six month period ended June 30, 2025 related
to our equity share of ILiAD net losses, as compared to a recognized net loss of $1,305,000 for the six months ended June 30, 2024. We
anticipate continuing to record our share of net losses from ILiAD.
Net
Loss. As a result of the foregoing, we realized a net loss of $826,000 or $0.04 per share basic and diluted for the six months ended
June 30, 2025, compared with a net loss of $1,578,000 or $0.07 per share basic and diluted for the six months ended June 30, 2024.
The reduction in net loss of $752,000 for the six months ended June 30, 2025, as compared to 2024, was primarily the result of decreased
recognized losses in our equity method investee of $564,000, decreased operating expenses of $127,000, increased other income of $115,000
and increased revenue of $50,000, offset by decreased income tax benefits of $104,000.
LIQUIDITY
AND CAPITAL RESOURCES
We
have financed our operations primarily from revenue from licensing our patents. At June 30, 2025 our principal sources of liquidity consisted
of cash and cash equivalents and marketable securities of $38,485,000 and working capital of $38,288,000. Based on our current cash position,
we believe that we will have sufficient cash to fund our operations for the next twelve months and the foreseeable future. Our patent
infringement litigation or realization of our investment in ILiAD may result in a material increase in our liquidity and capital resources.
Working
capital decreased by $1,778,000 at June 30, 2025 to $38,288,000 as compared to working capital of $40,066,000 at December 31, 2024.
The decrease in working capital was primarily due to payment of dividends of $1,155,000, the acquisition of patents of $414,000 and repurchases
of our common stock of $207,000.
Net
cash used in operating activities decreased by $158,000 to $502,000 for the six months ended June 30, 2025, from $660,000 for the six
months ended June 30, 2024. The decrease was primarily attributable to the decrease in our net loss of $752,000, offset by non-cash income
and expense items of $698,000, including reduced recognized losses of our equity method investee of $564,000. The decrease in cash used
in operating activities is also a result of a net decrease in cash used in operating assets and liabilities of $104,000, including decreased
cash used in payment of accrued expenses of $139,000, offset by decreased cash provided by accounts payable of $80,000.
Net
cash provided by investing activities during the six months ended June 30, 2025 decreased by $3,709,000 to $2,150,000 as compared to
$5,859,000 for the six months ended June 30, 2024, primarily as a result of decreased sales of marketable securities of $5,298,000, offset
by decreased purchases of marketable securities of $2,003,000 and the acquisition of patents in 2025 of $414,000.
Net
cash used in financing activities for the six months ended June 30, 2025 and 2024 was $1,369,000 and $2,156,000, respectively. The decrease
of $787,000 for the six months ended June 30, 2025 primarily resulted from a decrease of $676,000 in repurchases of our common stock.
We
maintain our cash in money market funds, government securities, certificates of deposit and short-term fixed income securities. Accordingly,
we do not believe that our investments have significant exposure to interest rate risk.
OFF-BALANCE
SHEET ARRANGEMENTS
We
do not have any off-balance sheet arrangements.
CONTRACTUAL
OBLIGATIONS
We
do not have any long-term debt, capital lease obligations, purchase obligations or other long-term liabilities.
CRITICAL
ACCOUNTING ESTIMATES
Our
unaudited condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our financial statements
included in this Quarterly Report on Form 10-Q requires management to make estimates that affect the reported amounts of assets, liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues
and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results,
our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other
assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available
information. We evaluate these estimates on an ongoing basis.
We
consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that
were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to
occur from the period to period or use of different estimates that we reasonably could have used in the current period, would have a
material impact on our financial condition or results of operations. There are items within our financial statements that require
estimation but are not deemed critical, as defined above.
For
a detailed discussion of our significant accounting policies and related judgements, see Note B to our consolidated financial statements
included herein.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not
Applicable
ITEM
4. CONTROLS AND PROCEDURES
(a)
Evaluation of Disclosure Controls and Procedures
Our
Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined
in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this Quarterly Report on Form 10-Q.
Based upon this review, these officers concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our
disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports we file or
submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in
applicable rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial
Officer, to allow timely decisions regarding required disclosure.
(b)
Changes in Internal Controls
There
was no change in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2025 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART
II. OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
For
a description of our legal proceedings see Note I to our unaudited condensed consolidated financial statements included in this Quarterly
Report and Item 3. Legal Proceedings of our Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the SEC on February
28, 2025). During the three months ended June 30, 2025 and to date, no material events occurred with respect to our legal proceedings,
except for the following: On June 27, 2025, we commenced patent litigation against Samsung Electronics Co., LTD and Samsung Electronics
America, Inc. (collectively, “Samsung”) in the United States District Court for the Eastern District of Texas, Marshall Division,
for infringement of certain patents within our M2M/IoT Patent Portfolio. The lawsuit alleges that Samsung infringes our patents by supporting
certain eSIM (embedded Subscriber Identification Module) and 5G technologies in its mobile devices, including its Galaxy smartphones,
watches and tablets (see Note I[1] to our unaudited condensed consolidated financial statements included herein).
ITEM
1A. RISK FACTORS
Our
operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition,
results of operations and the trading price of our common stock. Investors should carefully consider the risks described in this Quarterly
Report on Form 10-Q for the three months ended June 30, 2025, and our Annual Report on Form 10-K for the year ended December 31, 2024
(pages 10-19), filed with the SEC on February 28, 2025.
ITEM
2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent
Issuances of Unregistered Securities
There
were no such issuances during the three months ended June 30, 2025.
Stock
Repurchases
On
June 17, 2025, our Board of Directors authorized an extension and increase of the Share Repurchase Program to repurchase up to
$5,000,000 of shares of our common stock over the subsequent 24 month period. The common stock may be repurchased from time to time
in open market transactions or privately negotiated transactions at our discretion except for repurchases under our
10b5-1 plans. The timing and amount of the shares repurchased
is determined by management, except for repurchases under our 10b5-1 plans, based on its evaluation of market conditions and other factors. The Share Repurchase Program may be
increased, suspended or discontinued at any time. Since inception of the Share Repurchase Program in August 2011 through June 30,
2025, we have repurchased an aggregate of 10,525,705 shares of our common stock at an aggregate cost of $20,185,549 (exclusive of
commissions) or an average per share price of $1.92. During the three months ended June 30, 2025, we repurchased an aggregate of
44,811 shares of our common stock at an aggregate cost of $55,337 (exclusive of commissions) or an average per share price of $1.23.
During the six months ended June 30, 2025, we repurchased an aggregate of 151,473 shares of our common stock (exclusive of
commissions) or an average per share price of $1.33. At June 30, 2025, the remaining dollar value of shares that may be repurchased
under the Share Repurchase Program was $4,994,853.
During
the months of April, May and June 2025, we purchased common stock pursuant to our Share Repurchase Program as indicated below:
Period |
Total
Number of
Shares
Purchased |
Average
Price Paid
Per Share |
Total
Number
of Shares
Purchased as
Part of Publicly
Announced
Plans or
Programs |
Maximum
Number
(or Approximate
Dollar Value) of
Shares that May Yet
Be Purchased Under
the Plans or
Programs |
April
1 to April 30, 2025 |
30,359 |
$1.23 |
30,359 |
$2,918,059 |
May
1 to May 31, 2025 |
9,492 |
$1.25 |
9,492 |
$2,906,167 |
June
1 to June 30, 2025 |
4,960 |
$1.23 |
4,960 |
$4,994,853(1) |
Total |
44,811 |
$1.23 |
44,811 |
|
__________________
| (1) | Gives
effect to the Company’s extension of its Share Repurchase Program on June 17, 2025
to purchase up to $5,000,000 shares over the next two year period. |
ITEM
3. Defaults Upon Senior Securities
None
ITEM
5. OTHER INFORMATION
None
ITEM
6. Exhibits
(a)
Exhibits
| 31.1 | Controls
and Procedure Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.* |
| 31.2 | Controls
and Procedure Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.* |
| 32.1 | Certification
of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| 32.2 | Certification
of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| 101 | Interactive
data files:** |
| 101.INS | XBRL
Instance Document |
| 101.SCH | XBRL
Scheme Document |
| 101.CAL | XBRL
Calculation Linkbase Document |
| 101.DEF | XBRL
Definition Linkbase Document |
| 101.LAB | XBRL
Label Linkbase Document |
| 101.PRE | XBRL
Presentation Linkbase Document |
_____________________________
* Filed
herewith
** Furnished
herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
NETWORK-1 TECHNOLOGIES, INC. |
|
|
Date: August
8, 2025 |
By: |
/s/ Corey M. Horowitz |
|
|
Corey
M. Horowitz Chairman and Chief Executive Officer
(Principal
Executive Officer) |
|
|
Date: August
8, 2025 |
By: |
/s/ Robert Mahan |
|
|
Robert
Mahan Chief Financial Officer
(Principal
Financial Officer) |
30